Assuming RAF inhibitors that activated ERK1/2 in cardiomyocytes are useful for heart failure, it is necessary to consider whether using drugs to enhance ERK1/2 signalling for heart failure could increase the potential for unregulated cell proliferation or even cancer. Here, RAF1 is linked to heart failure.